COMFORT-II clinical trial: the 5 yr results

Claire Harrison, MD of the Guy’s and St. Thomas Hospital in London, UK, gives an overview of the latest results of the COMFORT-II clinical trial. This is a Phase 3 trial comparing the efficacy and safety of ruxolitinib in patients with myelofibrosis (MF).
At the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL, it was shown that after 5 years of the study 50 patients continued receiving ruxolitinib, the spleen response rate plateaued at approx. 50% and there was a 33% prolongation of survival for patients who received ruxolitinib, which increases to 56% when using the rank preserving structural failure time (RPSFT) statistical method. Dr Harrison also discusses other findings obtained in this study.